Andrew Seidman

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Introduction. Single-agent or combination chemotherapy in metastatic breast cancer
    Andrew Seidman
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncology (Williston Park) 17:9-14. 2003
  2. ncbi request reprint "Will weekly work"? Seems to be so
    Andrew D Seidman
    J Clin Oncol 23:5873-4. 2005
  3. ncbi request reprint Systemic treatment of breast cancer. Two decades of progress
    Andrew D Seidman
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 20:983-90; discussion 991-2, 997-8. 2006
  4. doi request reprint Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer
    Andrew D Seidman
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Division of Solid Tumor Oncology, New York, NY 10065, USA
    Clin Breast Cancer 13:239-246.e1. 2013
  5. doi request reprint Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer
    A D Seidman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Oncol 22:1094-101. 2011
  6. doi request reprint Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leu
    Andrew D Seidman
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 26:1642-9. 2008
  7. ncbi request reprint Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Andrew D Seidman
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 3:178-9. 2006
  8. ncbi request reprint Current status of dose-dense chemotherapy for breast cancer
    Andrew D Seidman
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Pharmacol 56:78-83. 2005
  9. ncbi request reprint Gemcitabine and docetaxel in metastatic breast cancer
    Andrew D Seidman
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 18:13-6. 2004
  10. ncbi request reprint Incorporating oral capecitabine into the treatment of breast cancer. Introduction
    Andrew D Seidman
    Memorial Sloan Kettering Cancer Center and Cornell University Medical College, New York, New York 10021, USA
    Oncologist 7:1-3. 2002

Detail Information

Publications55

  1. ncbi request reprint Introduction. Single-agent or combination chemotherapy in metastatic breast cancer
    Andrew Seidman
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncology (Williston Park) 17:9-14. 2003
  2. ncbi request reprint "Will weekly work"? Seems to be so
    Andrew D Seidman
    J Clin Oncol 23:5873-4. 2005
  3. ncbi request reprint Systemic treatment of breast cancer. Two decades of progress
    Andrew D Seidman
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 20:983-90; discussion 991-2, 997-8. 2006
    ..This review will highlight some of the landmark accomplishments during this time, and offer a glimpse at where we might be 20 years from now...
  4. doi request reprint Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer
    Andrew D Seidman
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Division of Solid Tumor Oncology, New York, NY 10065, USA
    Clin Breast Cancer 13:239-246.e1. 2013
    ..This trial was designed to further develop nab-P by evaluating its efficacy and safety using every 3 weeks (q3w), every 2 weeks (q2w), or weekly scheduling in combination with bevacizumab as first-line treatment of MBC...
  5. doi request reprint Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer
    A D Seidman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Oncol 22:1094-101. 2011
    ..Safety and efficacy of gemcitabine plus docetaxel (GD) and capecitabine plus docetaxel (CD) were compared in patients with metastatic breast cancer, where the alternate crossover monotherapy (GD→C or CD→G) was predetermined...
  6. doi request reprint Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leu
    Andrew D Seidman
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 26:1642-9. 2008
    ..Because inhibition of HER-family signaling had potential efficacy even without HER-2 overexpression, we randomly assigned for trastuzumab in this population...
  7. ncbi request reprint Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Andrew D Seidman
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 3:178-9. 2006
  8. ncbi request reprint Current status of dose-dense chemotherapy for breast cancer
    Andrew D Seidman
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Pharmacol 56:78-83. 2005
    ....
  9. ncbi request reprint Gemcitabine and docetaxel in metastatic breast cancer
    Andrew D Seidman
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 18:13-6. 2004
    ..Results of this trial will help to determine optimal use of taxane-based combinations in patients with advanced disease...
  10. ncbi request reprint Incorporating oral capecitabine into the treatment of breast cancer. Introduction
    Andrew D Seidman
    Memorial Sloan Kettering Cancer Center and Cornell University Medical College, New York, New York 10021, USA
    Oncologist 7:1-3. 2002
  11. ncbi request reprint Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    A D Seidman
    Breast Cancer Medicine Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:2587-95. 2001
    ..Efficacy was correlated with immunohistochemical and fluorescent in situ hybridization (FISH) assay results...
  12. ncbi request reprint Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer
    A D Seidman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 14:1877-84. 1996
    ..The tolerability of this strategy and its pharmacokinetic profile and pharmacodynamic correlates were also investigated...
  13. ncbi request reprint Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
    Andrew D Seidman
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center and Cornell University Medical College, New York, New York 10021, USA
    Oncologist 7:20-8. 2002
    ..In light of the confirmatory results of subsequent large trials, capecitabine is now considered a reference treatment in this setting, as no other agent has consistently demonstrated such high efficacy in as large a patient population...
  14. ncbi request reprint Gemcitabine as single-agent therapy in the management of advanced breast cancer
    A D Seidman
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncology (Williston Park) 15:11-4. 2001
    ..To this end, several recent clinical trials have evaluated the novel nucleoside analog gemcitabine (Gemzar) as single-agent therapy for advanced breast cancer. This article reviews these trials...
  15. ncbi request reprint Cardiac dysfunction in the trastuzumab clinical trials experience
    Andrew Seidman
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:1215-21. 2002
    ....
  16. doi request reprint The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 713, New York, NY 10021, USA
    J Clin Oncol 26:1216-22. 2008
    ..The primary end point was cardiac safety, and the secondary end points were time to recurrence and overall survival...
  17. doi request reprint A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011
    ..We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) → nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer...
  18. ncbi request reprint Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer
    Chau Dang
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, NewYork, NY, USA
    Cancer Treat Rev 29:453-6. 2003
  19. ncbi request reprint Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Invest 23:483-7. 2005
    ..046). Functional assessment of HER2 status may provide unique predictive information not seen with conventional assessments...
  20. ncbi request reprint Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
    Shanu Modi
    Breast Cancer Medicine Service, Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:3665-73. 2002
    ..To prospectively evaluate the association between tumor response, change in quality of life (QoL), and hospital expenditures in patients with metastatic breast cancer (MBC) receiving single-agent paclitaxel...
  21. ncbi request reprint A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy
    Arti Hurria
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Am Geriatr Soc 54:1119-24. 2006
    ..To examine the toxicity experienced by a cohort of older women receiving adjuvant chemotherapy for breast cancer and the longitudinal effect on their functional status and quality of life (QOL)...
  22. ncbi request reprint HER2 testing and correlation with efficacy of trastuzumab therapy
    Monica Fornier
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 16:1340-8, 1351-2; discussion 1352, 1355-8. 2002
    ..FISH is not as widely available and is more costly than immunohistochemistry, but economic modeling shows that it is the most effective (and cost-effective) option...
  23. pmc Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer
    Alison K Conlin
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 10:281-7. 2010
    ....
  24. ncbi request reprint A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 6:55-60. 2005
    ..Gemcitabine was delivered at a dose of 800 mg/m2 on days 1, 8, and 15 of a 28-day cycle until evidence of disease progression...
  25. ncbi request reprint A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer
    Shanu Modi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 7:270-7. 2006
    ..Preclinical studies have indicated a synergistic effect for the combination of anti-EGFR therapy plus paclitaxel in breast cancer models...
  26. pmc Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity
    Hong Lin
    Cellular Immunology Laboratory, Division of Hematology Oncology, Department of Pediatrics, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10065, USA
    Cancer Immunol Immunother 59:885-97. 2010
    ..01, both). The studies indicate that oral MBG promoted maturation of HPC to become functionally active myeloid cells and enhanced peripheral blood leukocyte recovery after chemotoxic bone marrow injury...
  27. doi request reprint Adjuvant taxanes: more to the story
    Devika Gajria
    Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Breast Cancer 10:S41-9. 2010
    ..In this overview, we will review some of the key trials that have advanced the standard of care in the adjuvant setting with regard to various chemotherapy combinations...
  28. pmc A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects
    Gary Deng
    Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Cancer Res Clin Oncol 135:1215-21. 2009
    ..Whether oral administration in human produces measurable immunologic effects, however, is unknown...
  29. doi request reprint Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities
    Alison K Conlin
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 8:215-23. 2008
    ..As these combinations are being investigated, parallel correlative studies aimed at enriching the population who will benefit most are under way...
  30. ncbi request reprint Single-agent gemcitabine in the treatment of advanced breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 4:S101-6. 2004
    ....
  31. ncbi request reprint Cardiac effects of adjuvant therapy for early breast cancer
    Maria Theodoulou
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 30:730-9. 2003
    ..One of the most serious side effects of adjuvant therapy of early breast cancer is cardiac toxicity. This article will provide an overview of the cardiac effects of adjuvant therapy in the treatment of early breast cancer...
  32. ncbi request reprint Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy
    Jennifer Wheler
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 33:672-80. 2006
    ..Still unanswered, however, are questions regarding optimal sequencing, selection of aromatase inhibitor, and duration of treatment. This review will provide an overview of the major studies with an emphasis on these important questions...
  33. pmc A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Maura N Dickler
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:7878-83. 2008
    ..To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth factor receptor (EGFR/HER1) and the vascular endothelial growth factor (VEGF) pathway...
  34. doi request reprint Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes
    Conleth G Murphy
    Department of Breast Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 9:S58-65. 2009
    ..Decision-making regarding treatment selection must take into account multiple patient and tumor factors. The therapeutic indices of the available treatments should be considered in the context of the individual patient...
  35. doi request reprint Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Departments of Radiology, Biostatistics, and Renal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:628-33. 2010
    ..We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)...
  36. ncbi request reprint Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients
    Gary Deng
    Memorial Sloan Kettering Cancer Center, 1429 First Ave, New York, NY 10021, USA
    J Clin Oncol 25:5584-90. 2007
    ..To determine the immediate and long-term effects of true acupuncture versus sham acupuncture on hot flash frequency in women with breast cancer...
  37. ncbi request reprint Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:223-7. 2007
    ..We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics...
  38. ncbi request reprint Critical review of current treatment strategies for advanced hormone insensitive breast cancer
    Catherine Van Poznak
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Invest 20:1-14. 2002
    ..This manuscript will provide a review of the current treatment strategies for advanced hormone insensitive breast cancer...
  39. ncbi request reprint Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer
    Catherine Van Poznak
    Breast Cancer Medicine Service, The Pathology Department, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2319-26. 2002
    ..g., HER2, EGFR), and estrogen receptors and progesterone receptors. These molecular markers and their correlation with clinical taxane sensitivity are investigated in this retrospective clinicopathologic study...
  40. ncbi request reprint Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4062-7. 2004
    ....
  41. ncbi request reprint Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:5754-61. 2004
    ..The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival...
  42. ncbi request reprint A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Breast Cancer Res Treat 90:157-63. 2005
    ..Breast cancer has variable expression of KIT and PDGFR therefore we conducted a phase II trial to evaluate the safety and efficacy of imatinib in patients with metastatic breast cancer (MBC)...
  43. ncbi request reprint An update on epidermal growth factor receptor inhibitors
    Shanu Modi
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 4:47-55. 2002
    ..Promising new compounds in the advanced stages of clinical testing are emphasized...
  44. ncbi request reprint Monotherapy options in the management of metastatic breast cancer
    Andrew D Seidman
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 30:6-10. 2003
    ..A similar approach should be applied when considering use of combinations of these agents versus single-agent treatment...
  45. pmc Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer
    Pamela Drullinsky
    Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center at Rockville Centre, 1000 North Village Ave, Rockville Centre, NY 11570, USA
    Clin Breast Cancer 10:440-4. 2010
    ..Randomized trials with other regimens demonstrate that dose-dense (DD) scheduling can offer greater efficacy. We investigated the feasibility of administering CMF using a DD schedule...
  46. doi request reprint Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastases
    Celina Ang
    Department of Medicine, Gastrointestinal Oncology Service, NY, USA
    Breast J 19:96-9. 2013
    ..HAI and systemic chemotherapy is feasible and can benefit selected patients with BCLM, who have progressed on prior therapies. Patients require close monitoring for treatment-limiting toxicities...
  47. ncbi request reprint Cardiac dysfunction associated with trastuzumab
    Karen Lisa Smith
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Drug Saf 5:619-29. 2006
    ..This article reviews the cardiac toxicity findings in key trastuzumab clinical trials and clinical characteristics of trastuzumab-associated cardiac toxicity...
  48. ncbi request reprint Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer
    Alison K Conlin
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Mol Diagn Ther 11:355-60. 2007
    ..This assay and others aim to help improve risk classification and recurrence prediction and, therefore, optimize selection of patients for adjuvant chemotherapy...
  49. ncbi request reprint Taxanes in breast cancer: an update
    Alison K Conlin
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 9:22-30. 2007
    ..Targeted therapies in combination with the taxanes have further improved survival for both early and metastatic disease. New formulations of taxanes may both improve antitumor activity and reduce toxicity...
  50. ncbi request reprint Point: combination versus single-agent chemotherapy: the argument for sequential single agents
    Alison K Conlin
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 5:668-72. 2007
    ..This article reviews several important clinical trials that address this issue, and argues for single-agent sequential therapy for most patients with metastatic breast cancer...
  51. ncbi request reprint Emerging targeted therapies for breast cancer
    Melissa L Johnson
    Joan and Sanford I Weill Medical College, Cornell University, New York, New York, USA
    Oncology (Williston Park) 19:611-8. 2005
    ..We will also describe recently completed and currently ongoing clinical trials investigating targeted therapies and their potential to augment standard breast cancer therapy...
  52. ncbi request reprint Combination versus sequential single-agent therapy in metastatic breast cancer
    David Miles
    ICRF Breast Cancer Biology Unit, Guy s and St Thomas Hospital, London, UK
    Oncologist 7:13-9. 2002
    ..This article expands on these issues by reviewing trials comparing combination regimens with sequential approaches...
  53. ncbi request reprint Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel
    Deborah Toppmeyer
    Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA
    Clin Cancer Res 8:670-8. 2002
    ..This Phase II study evaluated the safety/tolerability, pharmacokinetics, and efficacy of VX-710 plus paclitaxel in women with locally advanced or metastatic breast cancer who were refractory to prior paclitaxel therapy...
  54. ncbi request reprint Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?
    Andrew D Seidman
    J Clin Oncol 21:577-9. 2003
  55. ncbi request reprint Emerging targeted therapies for breast cancer
    Monica Arnedos
    Breast Unit, Department of Medicine, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Hematol Oncol Clin North Am 21:321-40. 2007
    ..Targeted therapies against these pathways have recently become one of the most active and promising areas of development in oncology...